| Title |
Clinical pharmacology and pharmacogenetics of thiopurines
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, May 2008
|
| DOI | 10.1007/s00228-008-0478-6 |
| Pubmed ID | |
| Authors |
Srikumar Sahasranaman, Danny Howard, Sandip Roy |
| Abstract |
The thiopurine drugs-azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine-are widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. However, thiopurine drugs have a relatively narrow therapeutic index and are capable of causing life-threatening toxicity, most often myelosuppression. Thiopurine S-methyltransferase (TPMT; EC 2.1.1.67), an enzyme that catalyzes S-methylation of these drugs, exhibits a genetic polymorphism in 10% of Caucasians, with 1/300 individuals having complete deficiency. Patients with intermediate or deficient TPMT activity are at risk for excessive toxicity after receiving standard doses of thiopurine medications. This report reviews the recent advances in the knowledge of the mechanism of action as well as the molecular basis and interethnic variations of TPMT and inosine triphosphate pyrophosphatase (ITPase; EC 3.6.1.19), another enzyme implicated in thiopurine toxicity. In addition, an update on pharmacokinetics, metabolism, drug-drug interactions, safety, and tolerability of thiopurine drugs is provided. |
Mendeley readers
The data shown below were compiled from readership statistics for 268 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 1% |
| Australia | 2 | <1% |
| Portugal | 1 | <1% |
| Argentina | 1 | <1% |
| Denmark | 1 | <1% |
| Unknown | 260 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 46 | 17% |
| Student > Master | 43 | 16% |
| Student > Ph. D. Student | 40 | 15% |
| Researcher | 26 | 10% |
| Other | 23 | 9% |
| Other | 43 | 16% |
| Unknown | 47 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 79 | 29% |
| Agricultural and Biological Sciences | 32 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 28 | 10% |
| Biochemistry, Genetics and Molecular Biology | 22 | 8% |
| Chemistry | 21 | 8% |
| Other | 29 | 11% |
| Unknown | 57 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2022.
All research outputs
#4,759,175
of 23,033,713 outputs
Outputs from European Journal of Clinical Pharmacology
#455
of 2,570 outputs
Outputs of similar age
#16,040
of 83,714 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#2
of 10 outputs
Altmetric has tracked 23,033,713 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,570 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 83,714 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.